RNAse monoclonal antibody-LL2-I-131-conjugate
Alternative Names: Monoclonal antibody LL2-I-131- RNAse conjugate; RNAse conjugate - Immunomedics; RNAse-LymphoCide conjugate - ImmunomedicsLatest Information Update: 27 Oct 2020
At a glance
- Originator Immunomedics; National Cancer Institute (USA)
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
- 31 Jul 2002 Discontinued - Preclinical for Non-Hodgkin's lymphoma in USA (unspecified route)
- 31 Jul 2002 Discontinued - Preclinical for Solid tumours in USA (unspecified route)